Pfizer, Protalix Enter Into Agreement To Develop Gaucher’s Disease Treatment
Pfizer and Protalix have entered into an agreement to develop and commercialise Taliglucerase Alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.